Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large B-cell lymphoma with clinically or biologically high-risk features

To the Editor:Diffuse large B-cell lymphoma(DLBCL)exhibits clinical significance and biological diversity.Over the last two decades,rituximab with cyclophosphamide,doxorubicin,vincristine,and prednisone(R-CHOP)has substantially improved outcomes for DLBCL patients.However,approximately one-third of DLBCL cases continue to experience disease progression,resulting in long-term survival ranging from 50%to 60%.[1]Efforts to improve DLBCL patient outcomes by modifying R-CHOP dosing schedules have yielded limited success,and the addition of new drugs has benefited only specific patient subgroups.Nevertheless,intensive immunochemotherapy(IIC)has demonstrated promise and cost-effectiveness in recent years.The regimen of dose-adjusted etoposide.